The Drug Controller General of India (DCGI) on 22 November 2010 banned manufacturing and sale of anti-obesity medicine Sibutramine and its combination drugs sold under various brands as a result of side effects in consumers. The ban follows the recommendation of an expert committee that came out on 12 November to suspend the drug. The committee was set up immediately after Sibutramine’s innovator company US-based Abbott Laboratories withdrew its brand from the Indian market on 25 October 2010. Abbott’s brand Leptos accounted for about a third of the 30 crore market of the drug. Indian drugmakers such as Microlabs, Emcure and Cipla also sell their own brands of Sibutramine. Sibutramine is the third drug used for treating diabetes and obesity that has been banned in India in the past two years. In October 2010 the DCGI had banned the import and manufacture of Rosiglitazone, an anti-diabetic drug due to adverse side effects.
DCGI Banned Sibutramine
Sibutramine, an anti-obesity drug was baned by DGCI.
.jpg){kind=logo}
Your career begins here! At Jagranjosh.com, our vision is to enable the youth to make informed life decisions, and our mission is to create credible and actionable content that answers questions or solves problems for India’s share of Next Billion Users. As India’s leading education and career guidance platform, we connect the dots for students, guiding them through every step of their journey—from excelling in school exams, board exams, and entrance tests to securing competitive jobs and building essential skills for their profession. With our deep expertise in exams and education, along with accurate information, expert insights, and interactive tools, we bridge the gap between education and opportunity, empowering students to confidently achieve their goals.
-1767177472744.jpg)
-1767091475678.jpg)
Comments
All Comments (0)
Join the conversation